<DOC>
	<DOCNO>NCT01247428</DOCNO>
	<brief_summary>The DESSOLVE I clinical trial ass safety performance sirolimus-eluting MiStent SES .</brief_summary>
	<brief_title>First-In-Human Trial MiStent Drug-Eluting Stent ( DES ) Coronary Artery Disease</brief_title>
	<detailed_description>The DESSOLVE I clinical trial ass safety performance sirolimus-eluting MiStent treatment improve coronary luminal diameter patient symptomatic ischemic heart disease due discrete de novo lesion &lt; 20 mm length native coronary artery reference vessel diameter 2.5 mm 3.5 mm .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Male/female patient 1885 year ; 2 . Stable unstable angina pectoris , ischemia , silent ischemia ; 3 . Planned single , de novo , type A , B1 B2 coronary lesion ; 4 . Target lesion locate native coronary artery ; 5 . Target lesion vessel diameter 2.5 3.5 mm amenable treatment maximum 23 mm long stent ; 6 . Target lesion &gt; 50 % diameter stenosis ; 7 . Patients eligible percutaneous coronary intervention ( PCI ) ; 8 . Acceptable candidate myocardial revascularization surgery ; 9 . A patient may one additional critical nontarget lesion . 10 . The patient provide write informed consent . 1 . Female childbearing potential form birth control confirm negative pregnancy test baseline ; 2 . Recent Qwave myocardial infarction occur &lt; 72 hour prior index procedure . Recent myocardial infarction elevate level cardiac marker ; 3 . Left ventricular ejection fraction &lt; 30 % ; 4 . Patients cardiogenic shock ; 5 . Cerebrovascular accident transient ischemic attack within 6 month ; 6 . Active GI bleed within three month ; 7 . Any prior true anaphylactic reaction contrast agent ; 8 . Patient receiving/scheduled receive chemotherapy within 30days index procedure ; 9 . Patient receive immunosuppressive therapy know lifelimiting immunosuppressive/autoimmune disease ; 10 . Renal dysfunction ( creatinine &gt; 2.0 mg/dL 177 µmol/L ) ; 11 . Platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ ; 12 . White blood cell count &lt; 3,000 cells/mm3 ; 13 . Hepatic disease ; 14 . Heart transplant recipient ; 15 . Known contraindication dual antiplatelet therapy ; 16 . Known hypersensitivity sirolimus , cobaltchromium , medication aspirin , heparin , three follow : clopidogrel bisulfate ( Plavix ) , ticlopidine ( Ticlid ) , Prasugrel ( Effient ) ; 17 . Life expectancy &lt; 12 month ; 18 . Any major medical condition may interfere optimal participation patient study ; 19 . Patient currently participating/planning participate investigational drug another device study prior complete 12months followup ; 20 . Target vessel ( ) treat within 10 mm proximal distal target lesion type PCI within year prior index procedure ; 21 . Planned actual target vessel ( ) treatment unapproved device , directional rotational coronary atherectomy , laser , cut balloon , transluminal extraction catheter prior stent placement ; 22 . Previous coronary intravascular brachytherapy ; 23 . Planned coronary angioplasty coronary artery bypass grafting ( CABG ) first 9 month index procedure ; 24 . Prior PCI nontarget vessel must least 30 day prior study enrollment ; 25 . The intent direct stent target lesion ; 26 . Angiographic Assessed prior stent placement ; Instent restenotic target lesion ; More one lesion require treatment target vessel ; Target vessel diameter &lt; 2.5 mm &gt; 3.5 mm ; Target lesion amenable treatment 23 mm long stent ; Unprotected coronary artery branch lesion ( ≥50 % DS ) ; Target lesion locate surgical bypass graft ; Total vessel occlusion ; Target lesion ostial location ; Target lesion locate lateral branch bifurcation &gt; 2.5mm require lateral branch stenting ; Calcified target lesion anticipate unsuccessful/impracticable predilation ; Target vessel excessive tortuosity proximal angulation ( &gt; 90 degree ) ; Thrombus present target vessel ; More one nontarget critical lesion ; Nontarget lesion treat index procedure meet follow criterion : Within target vessel ; Within bypass graft ; Left main location ; Chronic total occlusion ; Involves complex bifurcation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Drug-eluting Stent</keyword>
	<keyword>Sirolimus</keyword>
</DOC>